BITR-2101 is under clinical development by Boston Immune Technologies and Therapeutics and currently in Phase I for T-Cell Leukemia. According to GlobalData, Phase I drugs for T-Cell Leukemia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BITR-2101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BITR-2101 overview
BITR-2101 IS under development for the treatment of infectious diseases and relapsed or refractory non-Hodgkin’s lymphoma subgroups including cutaneous T cell lymphoma (CTCL), primary cutaneous peripheral T cell lymphoma (PTCL), adult T cell leukemia/lymphoma (ATLL), diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). The drug candidates are composed of a highly enriched population of immunosuppressive regulatory T cells (Tregs) that act by targeting tumor necrosis factor receptor 2 (TNFR2). These are developed based on DOMab technology platform. It is administered through intravenous route.
Boston Immune Technologies and Therapeutics overview
Boston Immune Technologies and Therapeutics develops novel tumor necrosis factor superfamily receptor antagonist antibodies. It is headquartered in Boston, Massachusetts, the US.
For a complete picture of BITR-2101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
